Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
SNS-032
Description:
SNS-032 is an investigational small-molecule inhibitor of cyclin-dependent kinases studied as an anticancer drug.
Related topics:
Cancer-related Molecular Pathways (11%),
Chronic Lymphocytic Leukemia Research (7%)
Wikidata ID:
wiki/Q27075347
OpenAlex ID:
keywords/sns-032
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
2017
·
Calla M Olson
, Baishan Jiang
, et al.
·
Nature Chemical Biology
·
570
Development of Cell-Cycle Inhibitors for Cancer Therapy
2009
·
M. A. Dickson
, Gary K. Schwartz
·
Current Oncology
·
281
PDF
Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma
2010
·
Wei-Gang Tong
, Rong Chen
, et al.
·
Journal of Clinical Oncology
·
231
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
2009
·
Rong Chen
, William G. Wierda
, et al.
·
Blood
·
219
PDF
Overview of CDK9 as a target in cancer research
2016
·
Fatima Morales
, Antonio Giordano
·
Cell Cycle
·
217
PDF
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
2009
·
Andrew Conroy
, David E. Stockett
, et al.
·
Cancer Chemotherapy and Pharmacology
·
135
Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
2013
·
J Lemke
, S von Karstedt
, et al.
·
Cell Death and Differentiation
·
134
PDF
Solvent-Induced Protein Precipitation for Drug Target Discovery on the Proteomic Scale
2019
·
Xiaolei Zhang
, Qi Wang
, et al.
·
Analytical Chemistry
·
126
A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors
2007
·
Elisabeth I. Heath
, Keith Bible
, et al.
·
Investigational New Drugs
·
123
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia
2010
·
Rong Chen
, Lei Guo
, et al.
·
Blood
·
120
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
2017
·
E I Andersson
, S Pützer
, et al.
·
Leukemia
·
100
Piperlongumine conjugates induce targeted protein degradation
2023
·
Jing Pei
, Yufeng Xiao
, et al.
·
Cell chemical biology
·
89
Cyclin-Dependent Kinase Modulators and Cancer Therapy
2012
·
Marialucia Gallorini
, Amelia Cataldi
, et al.
·
BioDrugs
·
82
CDK9 is a prognostic marker and therapeutic target in pancreatic cancer
2017
·
Anna-Laura Kretz
, Monika Schaum
, et al.
·
Tumor Biology
·
62
PDF
The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine
2011
·
E Walsby
, M Lazenby
, et al.
·
Leukemia
·
59
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma
2019
·
Jing Zhang
, Shenglan Liu
, et al.
·
Molecular Cancer
·
57
PDF
SNS-032 Prevents Tumor Cell-Induced Angiogenesis By Inhibiting Vascular Endothelial Growth Factor
2007
·
M. Aktar Ali
, Hak Choy
, et al.
·
Neoplasia
·
57
PDF
Cyclin-Dependent Kinase 7/9 Inhibitor SNS-032 Abrogates FIP1-like-1 Platelet-Derived Growth Factor Receptor α and Bcr-Abl Oncogene Addiction in Malignant Hematologic Cells
2012
·
Yongbin Wu
, Chun Chen
, et al.
·
Clinical Cancer Research
·
55
Degradation of Cyclin-Dependent Kinase 9/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs
2023
·
Yanping Zeng
, Jian Xiao
, et al.
·
Journal of Medicinal Chemistry
·
44
Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
2020
·
Elise Aasebø
, Frode S. Berven
, et al.
·
Cancers
·
44
TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells
2016
·
Diego De Miguel
, Ana Gallego-Lleyda
, et al.
·
Nanotechnology
·
43
The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo
2014
·
GUI’E XIE
, HONGPING TANG
, et al.
·
International Journal of Oncology
·
43
PDF
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells
2009
·
Elisabeth Kodym
, Reinhard Kodym
, et al.
·
Lung Cancer
·
43
Anti-EGFR Antibody–Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth
2024
·
Anthony Cheung
, Alicia M. Chenoweth
, et al.
·
Clinical Cancer Research
·
41
Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma
2021
·
Huishan Zeng
, Huiru Yang
, et al.
·
Cell Death and Disease
·
36
PDF
Show more works
View as search
Works count:
144
Citation count:
3,738
Year
Topic
Type